17/01/2026
A new combination - Alyftrek
CF is caused by mutations in the CFTR gene that result in the loss or dysfunction of the CFTR protein. This leads to the production of thick, sticky mucus that accumulates in the lungs, digestive system & other organs, ultimately driving most of the disease’s symptoms.
Alyftrek comprises a new combination of three CFTR modulators, a class of medications that can boost the function of the CFTR protein in patients carrying specific disease-causing mutations.
New CF treatment findings: https://bit.ly/3Zf6OOb
A new analysis of clinical trial data suggests that Alyftrek, a once-daily CFTR modulator, may improve quality of life more than Trikafta for children, teens, and adults living with cystic fibrosis.
Researchers looked beyond lung function to understand how people felt day to day, including physical activity, emotional well-being, and participation in school, work, and daily life.
Read more about what the study found and what it could mean for CF care at the link.